ANCA testing in monitoring the activity of the disease

Kidney and Blood Pressure Research

Volumn 26, Issue 4, 2003, Pages 226-230

  Cohen Tervaert, Jan Willem ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G3; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYELOBLASTIN; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISOLONE;

BLADDER CARCINOMA; CANCER RISK; CHURG STRAUSS SYNDROME; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; GLOMERULONEPHRITIS; HEMATURIA; HEMORRHAGIC CYSTITIS; HUMAN; IMMUNOFLUORESCENCE TEST; IMMUNOSUPPRESSIVE TREATMENT; INFERTILITY; KIDNEY BIOPSY; KIDNEY DISEASE; MICROSCOPIC POLYANGIITIS; MORBIDITY; MORTALITY; NEUTROPHIL; NONHUMAN; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; RELAPSE; REMISSION; SIDE EFFECT; VASCULITIS; WEGENER GRANULOMATOSIS;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; POPULATION SURVEILLANCE; RECURRENCE; RISK FACTORS; VASCULITIS;

EID: 0141867909     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000072989     Document Type: Conference Paper

References (35)

1. Langford CA: Treatment of ANCA-associated vasculitis. N Engl J Med 2003;349:3-4.
2. Jayne D, Rasmussen N, Andrassy K, et al: A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003;349:36-44.
3. Slot MC, Cohen Tervaert JW, Boomsma MM, Stegeman CA: A positive cANCA titer at switch to azathioprine therapy is associated with a disquieting relapse rate in PR3-ANCA-related vasculitis. Arthritis Rheum 2003; in press.
4. Stegeman CA: Anti-neutrophil cytoplasmic antibody (ANCA) levels directed against proteinase-3 and myeloperoxidase are helpful in predicting disease relapse in ANCA-associated small-vessel vasculitis. Nephrol Dial Transplant 2002;17:2077-2080.
5. Xiao H, Heeringa P, Hu P, et al: Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase (MPO-ANCA) cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002;110:955-963.
6. Huugen D, Xiao H, Esch van A, et al: Lipo-polysaccharide augments anti-myeloperoxidase antibody induced glomerulonephritis in mice (abstract). Kidney Blood Press Res 2003; in press.
7. Franssen CF, Stegeman CA, Oost-Kort WW, et al: Determinants of renal outcome in anti-myeloperoxidase-associated necrotizing crescentic glomerulonephritis. J Am Soc Nephrol 1998;9:1915-1923.
8. Stegeman CA, Tervaert JW, Sluiter WJ, Manson WL, de Jong PE, Kallenberg CG: Association of chronic nasal carriage ofStaphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med 1994;120:12-17.
9. Andrassy K, Waldherr R, Erb A, Ritz E: De novo glomerulonephritis in patients during remission from Wegener's granulomatosis. Clin Nephrol 1992;38:295-298.
10. Cohen Tervaert JW, van der Woude FJ, Fauci AS, et al: Association between active Wegener's granulomatosis and anticytoplasmic antibodies. Arch Intern Med 1989;149:2461-2465.
11. Boomsma MM, Stegeman CA, van der Leij MJ, et al: Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum 2000;43:2025-2033.
12. Cohen Tervaert JW, Goldschmeding R, Elema JD, et al: Association of autoantibodies to myeloperoxidase with different forms of vasculitis. Arthritis Rheum 1990;33:1264-1272.
13. Cohen Tervaert JW: The value of serial ANCA testing during follow-up studies in patients with ANCA-associated vasculitides: A review. J Nephrol 1996;9:232-240.
14. Boomsma MM, Stegeman CA, Kallenberg CG, Cohen Tervaert JW: Prevention of relapsing disease in anti-neutrophil cytoplasmic antibody related necrotizing small-vessel vasculitis: The role for autoantibody guided and anti-bacterial treatment; in Kallenberg CG, Cohen Tervaert JW (eds): Disease-Modifying Therapy in Vasculitides. Basel, Birkhäuser, 2001, pp 181-199.
15. Girard T, Mahr A, Noel LH, et al: Are antineutrophil cytoplasmic antibodies a marker predictive of relapse in Wegener's granulomatosis? A prospective study. Rheumatology (Oxford) 2001;40:147-151.
16. Gisslen K, Wieslander J, Westberg G, Herlitz H: Relationship between anti-neutrophil cytoplasmic antibody determined with conventional binding and the capture assay, and long-term clinical course in vasculitis. J Intern Med 2002;251:129-135.
17. Han WK, Choi HK, Roth RM, McCluskey RT, Niles JL: Serial ANCA titers: Useful tool for prevention of relapses in ANCA-associated vasculitis. Kidney Int 2003;63:1079-1085.
18. Boomsma MM, Stegeman CA, Hermans J, et al: Prevention of relapses in PR3 anti-neutrophil antibody (ANCA) associated vasculitis by treatment with azathioprine and corticosteroids: A multi-centre, randomized study (abstract). Kidney Blood Press Res 2003; in press.
19. Cohen Tervaert JW, Huitema MG, Hene RJ, et al: Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre. Lancet 1990;336:709-711.
20. Nowack R, Grab I, Flores-Suarez LF, Schnulle P, Yard B, van der Woude FJ: ANCA titres, even of IgG subclasses, and soluble CD14 fail to predict relapses in patients with ANCA-associated vasculitis. Nephrol Dial Transplant 2001;16:1631-1637.
21. Cohen Tervaert JW, Goldschmeding R, Elema JD, et al: Autoantibodies against myeloid lysosomal enzymes in crescentic glomerulonephritis. Kidney Int 1990;37:799-806.
22. Boomsma MM, Damoiseaux JG, Stegeman CA, et al: Image analysis: A novel approach for the quantification of antineutrophil cytoplasmic antibody levels in patients with Wegener's granulomatosis. J Immunol Methods 2003;274:27-35.
23. Dijstelbloem HM, Scheepers RH, Oost WW, et al: Fcgamma receptor polymorphisms in Wegener's granulomatosis: Risk factors for disease relapse. Arthritis Rheum 1999;42:1823-1827.
24. Reynolds WF, Stegeman CA, Cohen Tervaert JW: -463 G/A myeloperoxidase promoter polymorphism is associated with clinical manifestations and the course of disease in MPO-ANCA-associated vasculitis. Clin Immunol 2002;103:154-160.
25. Stassen P, Sanders J-S, Lems S, Cohen Tervaert JW, Stegeman CA: HLA DR antigens are associated with ANCA-associated vasculitis and relapse during follow up in PR3- but not in MPO-ANCA related vascultis (abstract). Kidney Blood Press Res 2003; in press.
26. Cohen Tervaert JW, Stegeman CA, Kallenberg CG: Silicon exposure and vasculitis. Curr Opin Rheumatol 1998;10:12-17.
27. Slot MC, Tervaert JW, Franssen CF, Stegeman CA: Renal survival and prognostic factors in patients with PR3-ANCA associated vasculitis with renal involvement. Kidney Int 2003;63:670-677.
28. Egner W, Chapel HM: Titration of antibodies against neutrophil cytoplasmic antigens is useful in monitoring disease activity in systemic vasculitides. Clin Exp Immunol 1990;82:244-249.
29. Chan TM, Frampton G, Jayne DR, Perry GJ, Lockwood CM, Cameron JS: Clinical significance of anti-endothelial cell antibodies in systemic vasculitis: A longitudinal study comparing anti-endothelial cell antibodies and anti-neutrophil cytoplasm antibodies. Am J Kidney Dis 1993;22:387-392.
30. Kerr GS, Fleisher TA, Hallahan CW, Leavitt RY, Fauci AS, Hoffman GS: Limited prognostic value of changes in antineutrophil cytoplasmic antibody titer in patients with Wegener's granulomatosis. Arthritis Rheum 1993;36:365-371.
31. Davenport A, Lock RJ, Wallington T: Clinical significance of the serial measurement of autoantibodies to neutrophil cytoplasm using a standard indirect immunofluorescence test. Am J Nephrol 1995;15:201-207.
32. Kyndt X, Reumaux D, Bridoux F, et al: Serial measurements of antineutrophil cytoplasmic autoantibodies in patients with systemic vasculitis. Am J Med 1999;106:527-533.
33. De'Oliviera J, Gaskin G, Dash A, Rees AJ, Pusey CD: Relationship between disease activity and anti-neutrophil cytoplasmic antibody concentration in long-term management of systemic vasculitis. Am J Kidney Dis 1995;25:380-389.
34. Jayne DR, Gaskin G, Pusey CD, Lockwood CM: ANCA and predicting relapse in systemic vasculitis. Q J Med 1995;88:127-133.
35. Ara J, Mirapeix E, Rodriguez R, Saurina A, Darnell A: Relationship between ANCA and disease activity in small vessel vasculitis patients with anti-MPO ANCA. Nephrol Dial Transplant 1999;14:1667-1672.